0001855450 false 0001855450 2023-05-10 2023-05-10 0001855450 LVAC:UnitsEachConsistingOfOneShareOfClassCommonStockParValue0.0001PerShareAndOnehalfOfOneRedeemableWarrantMember 2023-05-10 2023-05-10 0001855450 LVAC:ClassCommonStockParValue0.0001PerShareMember 2023-05-10 2023-05-10 0001855450 LVAC:RedeemableWarrantsExercisableForSharesOfClassCommonStockAtPriceOf11.50PerShareMember 2023-05-10 2023-05-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 10, 2023

 

LAVA MEDTECH ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40965   86-2973712

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)   (IRS Employer
Identification No.)

 

303 Wyman Street, Suite 300

Waltham, MA 02451

(Address of Principal Executive Offices) (Zip Code)

 

(781) 530-3868

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one share of Class A common stock, par value $0.0001 per share, and one-half of one redeemable warrant   LVACU   The Nasdaq Stock Market LLC
         
Class A common stock, par value $0.0001 per share   LVAC   The Nasdaq Stock Market LLC
         
Redeemable warrants, exercisable for shares of Class A common stock at a price of $11.50 per share   LVACW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

 

   

Item 8.01. Other Events.

 

As previously disclosed, the board of directors (the “Board”) of LAVA Medtech Acquisition Corp. (the “Company”) has elected to abandon and not implement the extension that was approved by stockholders on April 25, 2023 and intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Certificate of Incorporation.

 

The Company will redeem (the “Redemption”) all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering (the “Public Shares”), at a per-share redemption price of approximately $10.44 (the “Redemption Amount”) after the payment of taxes and dissolution expenses. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless. On the date of Redemption, the Public Shares will be deemed cancelled and will represent only the right to receive the Redemption Amount. The Redemption is expected to be completed on May 15, 2023.

 

The Company expects that The Nasdaq Stock Market LLC will file a Form 25 with the United States Securities and Exchange Commission (the “SEC”) to delist the Company’s securities. The Company thereafter expects to file a Form 15 with the SEC to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended. The Company anticipates that its securities, including the Public Shares, will cease trading at or around the close of business on May 12, 2023.

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LAVA MEDTECH ACQUISITION CORP.
   
  By: /s/ Anthony Natale
  Name: Anthony Natale
  Title: Chief Executive Officer

 

Dated: May 10, 2023

 

 

LAVA Medtech Acquisition (NASDAQ:LVAC)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more LAVA Medtech Acquisition Charts.
LAVA Medtech Acquisition (NASDAQ:LVAC)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more LAVA Medtech Acquisition Charts.